{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:53:54Z","timestamp":1792090434019,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>A limited number of studies have evaluated the effects of oral contraceptives (OCs) on the quality of life (QOL) of polycystic ovary syndrome (PCOS) patients. This study aimed to compare the effects of using OCs containing levonorgestrel (LNG) and those containing desogestrel (DSG), cyproterone acetate (CPA) or drospirenone (DRSP) for 6\u2009months on the QOL with PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this crossover randomized controlled 6-arm trial, 200 eligible patients with PCOS scheduled for OC therapy were randomly assigned to one of the 6 study arms. All 6 arms include two 6-month treatment periods, one period with OCs containing LNG, and the other with each of the 3 OCs containing DSG, CPA, or DRSP. Outcomes of interest were the total score of QOL and its domains, which were assessed using a specific and valid health-related quality of life questionnaire for PCOS, which is consisted of six domains, including psychosocial\u2013emotional, self-image, fertility, sexual function, hirsutism, and obesity\u2013 menstrual disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Finally, a total of 88 patients were analyzed for this study. The results showed that use of OCs containing DSG, CPA, and DRSP for 3\u2009months was not associated with significant differences in the total scores of QOL compared to those OCs containing LNG, whereas, after 6\u2009months of treatment, patients treated with OCs containing CPA had more improvements in their total scores of QOL, in comparison to OCs containing LNG (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.042). We found no significant differences in QoL domains, including psychosocial\u2013emotional, self-image, fertility, sexual function, hirsutism, and obesity-menstrual disorders after 3\u20136\u2009months of treatment with DSG, CPA, or DRSP, compared to LNG. The sequence and period effects were not significant in any of the analyses at 3 and 6\u2009months of treatment. The carry-over effect was not significant for most outcomes assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This crossover study demonstrated non-inferiority of OCs with newer generation progestins on different domains of QOL, in comparison with older compounds, although usage of products containing CPA was significantly associated with more improvement in total QOL of PCOS patients, compared to those containing LNG after 6-month of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/en.irct.ir\/trial\/519?revision=519\">IRCT201702071281N2<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12955-020-01544-4","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T08:03:04Z","timestamp":1598860984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial"],"prefix":"10.1186","volume":"18","author":[{"given":"Mina","family":"Amiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Nahidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh Bidhendi","family":"Yarandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Tohidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4609-065X","authenticated-orcid":false,"given":"Fahimeh Ramezani","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"1544_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/humrep\/der396","volume":"27","author":"B Fauser","year":"2012","unstructured":"Fauser B, Tarlatzis B, Rebar R, Legro R, Balen A, Lobo R, Carmina H, Chang R, Yildiz B, Laven J. Consensus on womens health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27:14\u201324.","journal-title":"Hum Reprod"},{"key":"1544_CR2","first-page":"1","volume":"6","author":"SM Sirmans","year":"2014","unstructured":"Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014;6:1.","journal-title":"Clin Epidemiol"},{"key":"1544_CR3","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1210\/jc.2017-02667","volume":"103","author":"TR Berni","year":"2018","unstructured":"Berni TR, Morgan CL, Berni ER, Rees DA. Polycystic ovary syndrome is associated with adverse mental health and neurodevelopmental outcomes. J Clin Endocrinol Metab. 2018;103:2116\u201325.","journal-title":"J Clin Endocrinol Metab"},{"key":"1544_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.psyneuen.2016.08.005","volume":"73","author":"CE Cesta","year":"2016","unstructured":"Cesta CE, M\u00e5nsson M, Palm C, Lichtenstein P, Iliadou AN, Land\u00e9n M. Polycystic ovary syndrome and psychiatric disorders: co-morbidity and heritability in a nationwide Swedish cohort. Psychoneuroendocrinology. 2016;73:196\u2013203.","journal-title":"Psychoneuroendocrinology"},{"key":"1544_CR5","doi-asserted-by":"publisher","first-page":"191. e191","DOI":"10.1016\/j.ajog.2017.04.034","volume":"217","author":"MP Diamond","year":"2017","unstructured":"Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson PA, Christman GM, Huang H, Hansen KR, Baker V. Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility. Am J Obstet Gynecol. 2017;217:191. e191\u201319.","journal-title":"Am J Obstet Gynecol"},{"key":"1544_CR6","doi-asserted-by":"crossref","unstructured":"Sidra S, Tariq MH, Farrukh MJ, Mohsin M. Evaluation of clinical manifestations, health risks, and quality of life among women with polycystic ovary syndrome. PLoS One. 2019;14.","DOI":"10.1371\/journal.pone.0223329"},{"key":"1544_CR7","doi-asserted-by":"crossref","unstructured":"Castelo-Branco C, Naumova I. Quality of life and sexual function in women with polycystic ovary syndrome: a comprehensive review. Gynecol Endocrinol. 2020;36:96\u2013103.","DOI":"10.1080\/09513590.2019.1670788"},{"key":"1544_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.mefs.2010.06.007","volume":"15","author":"R Taheripanah","year":"2010","unstructured":"Taheripanah R, Sepahvandi M, Entezari A, Amiri Z, Samani EN. Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients. Middle East Fertil Soc J. 2010;15:159\u201362.","journal-title":"Middle East Fertil Soc J"},{"key":"1544_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00404-019-05202-z","volume":"300","author":"P Angin","year":"2019","unstructured":"Angin P, Yoldemir T, Atasayan K. Quality of life among infertile PCOS patients. Arch Gynecol Obstet. 2019;300:461\u20137.","journal-title":"Arch Gynecol Obstet"},{"key":"1544_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/0167482X.2017.1311319","volume":"39","author":"L Borghi","year":"2018","unstructured":"Borghi L, Leone D, Vegni E, Galiano V, Lepadatu C, Sulpizio P, Garzia E. Psychological distress, anger and quality of life in polycystic ovary syndrome: associations with biochemical, phenotypical andsocio-demographic factors. J Psychosom Obstet Gynecol. 2018;39:128\u201337.","journal-title":"J Psychosom Obstet Gynecol"},{"key":"1544_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.fertnstert.2018.01.038","volume":"109","author":"A Dokras","year":"2018","unstructured":"Dokras A, Stener-Victorin E, Yildiz BO, Li R, Ottey S, Shah D, Epperson N, Teede H. Androgen excess-polycystic ovary syndrome society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. Fertil Steril. 2018;109:888\u201399.","journal-title":"Fertil Steril"},{"key":"1544_CR12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/09513590.2018.1460343","volume":"34","author":"ML Altinok","year":"2018","unstructured":"Altinok ML, Ravn P, Andersen M, Glintborg D. Effect of 12-month treatment with metformin and\/or oral contraceptives on health-related quality of life in polycystic ovary syndrome. Gynecol Endocrinol. 2018;34:859\u201363.","journal-title":"Gynecol Endocrinol"},{"key":"1544_CR13","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1210\/jc.2016-1896","volume":"101","author":"A Dokras","year":"2016","unstructured":"Dokras A, Sarwer DB, Allison KC, Milman L, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL, Estes SJ. Weight loss and lowering androgens predict improvements in health-related quality of life in women with PCOS. J Clin Endocrinol Metab. 2016;101:2966\u201374.","journal-title":"J Clin Endocrinol Metab"},{"key":"1544_CR14","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/humrep\/des113","volume":"27","author":"N Cinar","year":"2012","unstructured":"Cinar N, Harmanci A, Demir B, Yildiz BO. Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. Hum Reprod. 2012;27:1840\u20135.","journal-title":"Hum Reprod"},{"key":"1544_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpag.2013.09.011","volume":"27","author":"JP Chung","year":"2014","unstructured":"Chung JP, Yiu AK, Chung TK, Chan SS. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome. J Pediatr Adolesc Gynecol. 2014;27:166\u201371.","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"1544_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1741-7015-8-18","volume":"8","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.","journal-title":"BMC Med"},{"key":"1544_CR17","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/jc.2006-0178","volume":"91","author":"R Azziz","year":"2006","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91:4237\u201345.","journal-title":"J Clin Endocrinol Metab"},{"key":"1544_CR18","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"91","author":"R Azziz","year":"2009","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456\u201388.","journal-title":"Fertil Steril"},{"key":"1544_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jama.1968.03140060001001","volume":"203","author":"L Chiazze","year":"1968","unstructured":"Chiazze L, Brayer FT, Macisco JJ, Parker MP, Duffy BJ. The length and variability of the human menstrual cycle. JAMA. 1968;203:377\u201380.","journal-title":"JAMA"},{"key":"1544_CR20","first-page":"77","volume":"12","author":"AE Treloar","year":"1967","unstructured":"Treloar AE. Variation of the human menstrual cycle through reproductive life. Int J Fertil. 1967;12:77\u2013126.","journal-title":"Int J Fertil"},{"key":"1544_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/humupd\/dmr042","volume":"18","author":"H Escobar-Morreale","year":"2012","unstructured":"Escobar-Morreale H, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne C, Witchel S. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the androgen excess and polycystic ovary syndrome society. Hum Reprod Update. 2012;18:146\u201370.","journal-title":"Hum Reprod Update"},{"key":"1544_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4158\/EP.7.2.120","volume":"7","author":"N Goodman","year":"2001","unstructured":"Goodman N, Bledsoe M, Cobin R, Futterweit W, Goldzieher J, Petak S, Smith K, Steinberger E, Force AAoCEHDT. American Association of Clinical Endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders. Endocr Pract. 2001;7:120.","journal-title":"Endocr Pract"},{"key":"1544_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pdpdt.2010.01.003","volume":"7","author":"X-L Wang","year":"2010","unstructured":"Wang X-L, Wang H-W, Zhang L-L, Guo M-X, Huang Z. Topical ALA PDT for the treatment of severe acne vulgaris. Photodiagn Photodyn Ther. 2010;7:33\u20138.","journal-title":"Photodiagn Photodyn Ther"},{"key":"1544_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2133.1977.tb15179.x","volume":"97","author":"E Ludwig","year":"1977","unstructured":"Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97:247\u201354.","journal-title":"Br J Dermatol"},{"key":"1544_CR25","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/clinchem\/33.8.1372","volume":"33","author":"TJ WIlke","year":"1987","unstructured":"WIlke TJ, Utley DJ. Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin. Clin Chem. 1987;33:1372\u20135.","journal-title":"Clin Chem"},{"key":"1544_CR26","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/humrep\/deg115","volume":"18","author":"S Jonard","year":"2003","unstructured":"Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod. 2003;18:598\u2013603.","journal-title":"Hum Reprod"},{"key":"1544_CR27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1590\/S0034-89102003000600016","volume":"37","author":"M Fleck","year":"2003","unstructured":"Fleck M, Chachamovich E, Trentini CM. WHOQOL-OLD project: method and focus group results in Brazil. Rev Saude Publica. 2003;37:793\u20139.","journal-title":"Rev Saude Publica"},{"key":"1544_CR28","doi-asserted-by":"crossref","unstructured":"Nasiri-Amiri F, Tehrani FR, Simbar M, Montazeri A, Mohammadpour RA. The polycystic ovary syndrome health-related quality-of-life questionnaire: confirmatory factor analysis. Int J Endocrinol Metab. 2018;16.","DOI":"10.5812\/ijem.12400"},{"key":"1544_CR29","doi-asserted-by":"crossref","unstructured":"Diggle P, Diggle PJ, Heagerty P, Heagerty PJ, Liang K-Y, Zeger S. Analysis of longitudinal ; data. United Kingdom: Oxford University Press; 2002.","DOI":"10.1093\/oso\/9780198524847.001.0001"},{"key":"1544_CR30","doi-asserted-by":"crossref","unstructured":"Chow S-C, Liu J-P. Design and analysis of bioavailability and bioequivalence studies. New York: CRC press; 1999.","DOI":"10.1201\/9781420002027"},{"key":"1544_CR31","doi-asserted-by":"crossref","unstructured":"Jones B, Kenward MG: Design and analysis of cross-over trials. London: Chapman and Hall\/CRC; 2014. p. 1\u2013412.","DOI":"10.1201\/b17537"},{"key":"1544_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0197-2456(82)90024-1","volume":"3","author":"WC Blackwelder","year":"1982","unstructured":"Blackwelder WC. \u201cProving the null hypothesis\u201d in clinical trials. Control Clin Trials. 1982;3:345\u201353.","journal-title":"Control Clin Trials"},{"key":"1544_CR33","first-page":"301","volume":"76","author":"C O'Brien","year":"2008","unstructured":"O'Brien C. Sample size calculations in clinical research, by Shein-Chung Chow, Jun Shao, Hansheng Wang. Int Stat Rev. 2008;76:301\u20132.","journal-title":"Int Stat Rev"},{"key":"1544_CR34","doi-asserted-by":"crossref","unstructured":"Kazemi M, McBreairty LE, Zello GA, Pierson RA, Gordon JJ, Serrao SB, Chilibeck PD, Chizen DR. A pulse-based diet and the Therapeutic Lifestyle Changes diet in combination with health counseling and exercise improve health-related quality of life in women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial. J Psychosom Obstet Gynaecol. 2020;41:144\u201353.","DOI":"10.1080\/0167482X.2019.1666820"},{"key":"1544_CR35","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/humrep\/dey256","volume":"33","author":"HJ Teede","year":"2018","unstructured":"Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33:1602\u201318.","journal-title":"Hum Reprod"},{"key":"1544_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R, Guidelines RotAAOCP. American Association of Clinical Endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1\u2013203.","journal-title":"Endocr Pract"},{"key":"1544_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/13625187.2017.1317735","volume":"22","author":"X Ruan","year":"2017","unstructured":"Ruan X, Kubba A, Aguilar A, Mueck A. Use of cyproterone acetate\/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects. Eur J Contracept Reprod Health Care. 2017;22:183\u201390.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"1544_CR38","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1210\/jc.2003-031158","volume":"89","author":"M Guido","year":"2004","unstructured":"Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004;89:2817\u201323.","journal-title":"J Clin Endocrinol Metab"},{"key":"1544_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.fertnstert.2012.06.035","volume":"98","author":"SM Bhattacharya","year":"2012","unstructured":"Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98:1053\u20139.","journal-title":"Fertil Steril"},{"key":"1544_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/13625187.2018.1435779","volume":"23","author":"M Amiri","year":"2018","unstructured":"Amiri M, Kabir A, Nahidi F, Shekofteh M, Ramezani Tehrani F. Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2018;23:64\u201377.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"1544_CR41","doi-asserted-by":"crossref","unstructured":"Amiri M, Nahidi F, Bidhendi-Yarandi R, Khalili D, Tohidi M, Ramezani Tehrani F. A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. Human Reproduction. 2020;35:175\u201376.","DOI":"10.1093\/humrep\/dez255"},{"key":"1544_CR42","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.4158\/EP15748.DSC","volume":"21","author":"NF Goodman","year":"2015","unstructured":"Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocr Pract. 2015;21:1291\u2013300.","journal-title":"Endocr Pract"},{"key":"1544_CR43","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00404-011-1947-1","volume":"284","author":"X Shi","year":"2011","unstructured":"Shi X, Zhang L, Fu S, Li N. Co-involvement of psychological and neurological abnormalities in infertility with polycystic ovarian syndrome. Arch Gynecol Obstet. 2011;284:773\u20138.","journal-title":"Arch Gynecol Obstet"},{"key":"1544_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/cen.13858","volume":"90","author":"M Amiri","year":"2019","unstructured":"Amiri M, Bidhendi Yarandi R, Nahidi F, Tohidi M, Ramezani Tehrani F. The relationship between clinical and biochemical characteristics and quality of life in patients with polycystic ovary syndrome. Clin Endocrinol. 2019;90:129\u201337.","journal-title":"Clin Endocrinol"},{"key":"1544_CR45","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.9024","volume":"7","author":"M Amiri","year":"2018","unstructured":"Amiri M, Tehrani FR, Nahidi F, Kabir A, Azizi F. Comparing the effects of combined oral contraceptives containing progestins with low androgenic and antiandrogenic activities on the hypothalamic-pituitary-gonadal axis in patients with polycystic ovary syndrome: systematic review and meta-analysis. JMIR Res Protoc. 2018;7:e113.","journal-title":"JMIR Res Protoc"},{"key":"1544_CR46","volume-title":"Guidelines for calculating sample size in 2x2 crossover trials: a simulation study","author":"N Siyasinghe","year":"2011","unstructured":"Siyasinghe N, Sooriyarachchi R. Guidelines for calculating sample size in 2x2 crossover trials: a simulation study; 2011."},{"key":"1544_CR47","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/sim.4497","volume":"31","author":"WK Ho","year":"2012","unstructured":"Ho WK, Matthews JN, Henderson R, Farewell D, Rodgers LR. Dropouts in the AB\/BA crossover design. Stat Med. 2012;31:1675\u201387.","journal-title":"Stat Med"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-020-01544-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-020-01544-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-020-01544-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T17:50:52Z","timestamp":1723485052000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-020-01544-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1186\/s12955-020-01544-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-22295\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22295\/v2","asserted-by":"object"}]},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"9 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the ethics committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran. (Ethics Code: IR.SBMU.ENDOCRINE.REC.1396.425). We obtained written informed consent from all eligible participants, following study content being clearly explained to the subjects by the trial assistant; all research tools, including questionnaires, were completely anonymous.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"293"}}